Samsung, Sandoz sign deal to commercialize biosimilar SB17

신하늬 2023. 9. 11. 16:28
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

닫기
Samsung Bioepis signed an agreement with Switzerland’s Sandoz for the sales of its Stelara biosimilar drug in the North American and European regions.

Samsung Bioepis headquarters in Songdo, Incheon [SAMSUNG BIOEPIS]

Samsung Bioepis headquarters in Songdo, Incheon [SAMSUNG BIOEPIS]

Samsung Bioepis signed an agreement with Switzerland’s Sandoz for the sales of its Stelara biosimilar drug in the North American and European regions.

Samsung Bioepis’ SB17, a proposed biosimilar to Janssen Pharmaceuticals’ blockbuster psoriasis treatment Stelara, is the Incheon-based biopharmaceutical company’s fourth biosimilar candidate in the immunology pipeline.

In March, the company presented its Phase 1 clinical study results for SB17. Phase 3 was completed in December last year.

Stelara is the brand name for the ustekinumab drug. The global ustekinumab market size reached $17.7 billion in 2022, according to market tracker Iqvia.

BY SHIN HA-NEE [shin.hanee@joongang.co.kr]

Copyright © 코리아중앙데일리. 무단전재 및 재배포 금지.

이 기사에 대해 어떻게 생각하시나요?
코리아중앙데일리에서 직접 확인하세요. 해당 언론사로 이동합니다.